Feb. 17, 2015 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA) today reported its financial results ... from the sale of approximately 1.7 million shares of common stock through the Company's "At the Market" …
Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA) provided a corporate update and reviewed key ... expenses (which is net of Mylan's share of collaboration expenses), excluding stock-based compensation expense and net of collaborative …
Momenta Pharmacueticals (NASDAQ: MNTA) shares traded down early on Monday after a court ... Interested in getting more information about stock trends on social media? Signup for the Social Market Analytics newsletter on their website.
MNTA) jumped after the company reported positive results from a drug trial. Image source: Getty Images. Bookseller Barnes & Noble reported a decline in holiday sales that was worse than expected, and its stock plummeted 14.2%. …
Momenta Pharmaceuticals Inc. ( MNTA) reported first quarter 2013 net loss per share ... Momenta confirmed its 2013 guidance with total operating expenses, excluding stock-based compensation and net of collaborative revenues, …
Momenta Pharmaceuticals Inc. (NASDAQ: MNTA) was started as Overweight at JPMorgan on Friday, and the firm assigned a $26 price target. This implied 46% upside from the prior $17.76 close, although Momenta shares rose …
MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today announced that it has received commitments from selected investors to purchase 2.8 million shares of its common stock at a …
This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on MNTA at https://www.zacks.com/ap/MNTA Keywords: Momenta …
Shares of Momenta Pharmaceuticals Inc. MNTA were down 12.6% after the company reported disappointing ... However, revenues were down 17.3% from the year-ago quarter. Momenta’s stock has decreased 15.1% year to date compared …
Mylan’s stock has fallen 16.2% in the last six months compared with ... Meanwhile, Momenta Pharmaceuticals, Inc. MNTA along with Sandoz is looking to get approval for their generic version (Glatopa 40 mg) of 40-mg thrice-weekly …